# Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

> **NCT00632359** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00632359
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00632359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00632359, "Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00632359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*